HC Wainwright Issues Negative Outlook for ACTU Earnings

Key Points

• HC Wainwright has revised its Q3 2025 EPS estimate for Actuate Therapeutics down to ($0.25), from a previous estimate of ($0.18), while maintaining a "Buy" rating and a $20.00 price target for the stock.
• Actuate Therapeutics' shares have recently declined 3.4% and are trading at $7.97, with a one-year price range from $5.47 to $11.99.
• Insider transactions show significant activity, as Director Aaron G.L. Fletcher purchased 71,428 shares at $7.00 each, increasing his position by 57.14%.

Actuate Therapeutics, Inc. (NASDAQ:ACTU - Free Report) - Equities research analysts at HC Wainwright lowered their Q3 2025 earnings per share (EPS) estimates for Actuate Therapeutics in a report released on Monday, August 18th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($0.25) for the quarter, down from their previous forecast of ($0.18). HC Wainwright has a "Buy" rating and a $20.00 price target on the stock. HC Wainwright also issued estimates for Actuate Therapeutics' Q4 2025 earnings at ($0.25) EPS, FY2025 earnings at ($1.05) EPS and FY2026 earnings at ($1.02) EPS.

Actuate Therapeutics (NASDAQ:ACTU - Get Free Report) last posted its quarterly earnings results on Thursday, August 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.11).

Separately, Wall Street Zen cut Actuate Therapeutics from a "hold" rating to a "sell" rating in a report on Friday. Two investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $20.50.

Actuate Therapeutics Price Performance

ACTU traded down $0.07 during midday trading on Wednesday, reaching $8.29. 16,775 shares of the company were exchanged, compared to its average volume of 67,163. Actuate Therapeutics has a one year low of $5.47 and a one year high of $11.99. The stock's 50-day simple moving average is $7.05 and its 200 day simple moving average is $7.92.

Institutional Trading of Actuate Therapeutics

A number of institutional investors have recently modified their holdings of the stock. BIOS Capital Management LP raised its holdings in shares of Actuate Therapeutics by 0.7% during the 2nd quarter. BIOS Capital Management LP now owns 9,965,079 shares of the company's stock worth $60,887,000 after buying an additional 71,428 shares in the last quarter. Voss Capital LP grew its position in shares of Actuate Therapeutics by 101.0% in the 2nd quarter. Voss Capital LP now owns 286,140 shares of the company's stock valued at $1,748,000 after buying an additional 143,759 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Actuate Therapeutics by 252.5% in the 2nd quarter. Geode Capital Management LLC now owns 118,050 shares of the company's stock valued at $721,000 after buying an additional 84,561 shares during the last quarter. Sigma Planning Corp grew its position in shares of Actuate Therapeutics by 47.3% in the 1st quarter. Sigma Planning Corp now owns 23,675 shares of the company's stock valued at $160,000 after buying an additional 7,600 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its position in shares of Actuate Therapeutics by 98.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 22,358 shares of the company's stock valued at $151,000 after buying an additional 11,105 shares during the last quarter.

Insider Activity at Actuate Therapeutics

In other Actuate Therapeutics news, Director Aaron G.L. Fletcher bought 71,428 shares of Actuate Therapeutics stock in a transaction dated Friday, June 27th. The stock was bought at an average cost of $7.00 per share, for a total transaction of $499,996.00. Following the purchase, the director owned 196,428 shares of the company's stock, valued at $1,374,996. The trade was a 57.14% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Equity Cof Lp Bios bought 71,428 shares of Actuate Therapeutics stock in a transaction dated Friday, June 27th. The shares were acquired at an average price of $7.00 per share, with a total value of $499,996.00. Following the completion of the purchase, the director directly owned 196,428 shares in the company, valued at $1,374,996. This trade represents a 57.14% increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders have bought 214,284 shares of company stock valued at $1,499,988. 69.34% of the stock is owned by insiders.

About Actuate Therapeutics

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.